Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients

Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients

Abstract Background Glatiramer acetate (GA) is one of the first therapies approved for multiple sclerosis (MS). We prospectively included and monitored drug-naïve and pre-treated MS patients who had been prescribed GA for 1 year, to investigate reasons for GA prescription, its effectiveness and safe...

Full description

Bibliographic Details
Main Authors: Chiara Zecca, Giulio Disanto, Rosaria Sacco, Gianna C. Riccitelli, Claudio Gobbi
Format: Article
Language:English
Published: BMC 2019-07-01
Series:BMC Neurology
Subjects:
CIS
GA
Glatiramer acetate
Multiple sclerosis
Relapsing remitting
Therapy
Online Access:http://link.springer.com/article/10.1186/s12883-019-1383-6

Internet

http://link.springer.com/article/10.1186/s12883-019-1383-6

Similar Items